Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Researchers have engineered a tri‑specific scaffold cell (TriSC) platform in the probiotic strain *Escherichia coli* Nissle 1917 that uses three orthogonal coiled‑coil motifs to create a programmable, reversible surface. The system enables simultaneous, selective attachment of multiple nanobody cargos and a fluorescent reporter without genetic fusion. In vitro tests show that co‑displaying DR5‑agonistic and EGFR‑targeting nanobodies on the bacterial surface produces synergistic anticancer activity. The mix‑and‑go approach offers a dynamic, multiplexed strategy for next‑generation live biotherapeutics.
The future of promising therapeutics is on the line in the Trump administration's FDA, says the agency's former commissioner https://t.co/vyt49FkDsb
Good news for America’s children. ACIP was devoid of vaccine expertise and made harmful and ideologically driven recommendations that went against pediatric medical science. Hopefully we can rebuild pubic confidence in vaccines despite their efforts to undermine it, but it...
The review of Aimee Donnellan’s book Off the Scales examines how Ozempic, a GLP‑1 drug originally for type‑2 diabetes, has become a blockbuster obesity treatment. It details the drug’s ability to deliver rapid 20%‑plus weight loss, its side‑effect profile, and...
The FDA approved Rhythm Pharmaceuticals' once‑daily injection Imcivree for acquired hypothalamic obesity in adults and children aged four and up. Clinical trials showed an 18‑percentage‑point weight‑loss advantage over placebo, making it the first therapy for this rare, brain‑injury‑driven condition. Rhythm...
Roche’s Genentech has halted the Phase III development of its muscle‑preserving therapy for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). The decision follows disappointing efficacy signals and safety concerns that emerged in late‑stage trials. The program also included an...
Association of epigenetic age acceleration with MRI biomarkers of aging and Alzheimer's disease neurodegeneration https://t.co/VSJVp4MYij
Researchers created a single‑cell, subcellular proteome atlas of replicative aging in yeast, revealing hundreds of previously unknown protein changes tied to the classic hallmarks of aging. Spatial analysis showed that hallmark phenotypes often manifest as compartment‑specific relocalization and aggregation. Over...
NICE has agreed to revisit its June 2025 rejection of Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) for NHS reimbursement. The appeal will send the dossiers back to the appraisal committee to re‑examine clinical benefits, long‑term data, infusion costs and unpaid...
Novo Nordisk received FDA clearance for a 7.2‑milligram version of its obesity drug Wegovy, slated for U.S. pharmacy launch in April. The higher dose showed about 19% average weight loss in trials, positioning the Danish firm to better compete with...
Shionogi announced the first patient enrollment in its global Phase II Esprit trial, evaluating the oral substrate‑reduction therapy S‑606001 in adults with late‑onset Pompe disease. The 52‑week, double‑blind, placebo‑controlled study will run across the EU, the UK and the United States,...
Researchers at Technion’s Levenberg Laboratory have created a first‑of‑its‑kind three‑dimensional implant that merges muscle, fat, a hierarchical blood vessel network and, uniquely, a lymphatic system. The construct is printed with a custom extracellular‑matrix bio‑ink and matured in a flow‑controlled bioreactor....
Psychedelic research has surged, but recent psilocybin trials reveal modest benefits that fail to outpace placebo. A German study with 144 treatment‑resistant depression patients found no statistically significant advantage for high‑dose psilocybin. An open‑label review of 24 trials concluded psychedelics...
$NVS paying $2bn for Synnovation's SNV4818, after $LLY paid $1.5bn for Scorpion's STX-478. Mechanistically, seems like good news for $RLAY, bad for $OKUR & $COGT
LivaNova received FDA Premarket Approval for its aura6000 neurostimulation system, targeting adults with moderate‑to‑severe obstructive sleep apnea (OSA) who cannot use or have failed first‑line therapies. The approval is based on the OSPREY randomized controlled trial, which showed a 65%...
#compchem #machinelearning #quantumcomputing New preprint: "The Convergence Frontier: Integrating Machine Learning and High Performance Quantum Computing for Next-Generation Drug Discovery". @qubit_pharma https://t.co/4D23DV0uAk
Making good progress on my vibecoded mutagenesis tool. Now it makes golden braid part domestication easy too. I may disappoint Patrick and just make a plasmid editor that works inside your terminal with external GUI libraries necessary aside from Textual...
![[Editorial] Making Treatment for Obesity More Equitable](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/9ad50868737552068254155c5d608c4d.webp)
2026 could be a watershed year for obesity treatment as GLP‑1 receptor agonists cement their role after a decade of clinical success. The global market for weight‑loss drugs is forecast to hit US$150 billion by 2035, reflecting soaring demand. More than...
Single-cell aging clocks: A precision tool for dissecting and targeting the aging process https://t.co/5e47qWtZwH https://t.co/ImfBb45luO
A two‑year pilot trial published in JAMA Neurology found that low‑dose oral lithium (150‑300 mg daily) slowed verbal memory decline in older adults with mild cognitive impairment. The neuroprotective benefit was most pronounced in participants who tested positive for amyloid‑beta, a...
The European Union’s proposed Biotech Act seeks to streamline fragmented regulatory procedures, create coordinated clinical‑trial pathways, and introduce new instruments such as regulatory sandboxes and data‑quality accelerators. By aligning biotech oversight with the AI Act and the European Health Data...
Researchers at VIB‑KU Leuven and the Francis Crick Institute discovered that alveolar type II (AT2) cells in the lung are reprogrammed by metastatic breast cancer to overproduce lipids, creating a nutrient‑rich niche that fuels tumor growth. The study showed that...
Researchers from Denmark and collaborators reported that the hormone GDF15, known for causing nausea in early pregnancy, appears to rise in response to chronic alcohol consumption and may act as a feedback signal limiting intake. Small human studies at Oktoberfest...
Researchers from UCLA, Stanford, Utah, and Columbia have engineered T cell receptors to strengthen catch‑bond interactions with prostate cancer antigens, improving cytotoxic function. By altering just one or two amino acids in the TCR, the modified cells exhibit longer bond...
Bio‑Sourcing and The Tiny Cargo Company announced a strategic collaboration to co‑develop orally delivered monoclonal antibody therapies using goat‑milk‑derived exosomes. The partnership merges Bio‑Sourcing’s BioMilk platform, which produces high‑yield antibodies and milk extracellular vesicles in transgenic goats, with Tiny Cargo’s...
Life Without a Pulse: Continuous-Flow VAD That Sustains Patients Awaiting Transplants by @Doctors__squad #HealthTech #Innovation #EmergingTech #Tech #Technology #TechForGood https://t.co/KoRFzmH3lQ
Guggenheim Securities reaffirmed a Buy rating on Larimar Therapeutics and held its $26 price target after the company disclosed a $115 million public offering and FDA Breakthrough Therapy Designation for its Friedreich's ataxia drug. The analyst’s confidence comes amid a cash...
Scientists at University College London have engineered bio‑grown oesophageal segments using patient‑derived stem cells and implanted them into minipigs, restoring normal swallowing. The grafts were seeded onto decellularized scaffolds, covered with a biodegradable mesh, and integrated functional muscle, nerves, and...
China’s biotech sector is experiencing a rapid surge, now hosting more CAR‑T cell trials than the United States. The growth is driven by a dual‑track regulatory framework that enables fast‑track, investigator‑initiated trials with minimal red tape. U.S. experts warn that...
Researchers at the Institute of Physical Chemistry (IPC PAS) and the University of Warsaw have created a magnetic‑field‑driven system that arranges endothelial‑cell‑coated microparticles into predefined lattices, prompting the growth of microvascular networks with precise architecture. By using super‑paramagnetic beads and micromagnets,...
Recursion Pharmaceuticals CEO Najat Khan says AI’s worth will be judged by the medicines it helps create, not by the sophistication of the tools. She emphasizes deploying AI selectively in chemistry, trial execution, and out‑of‑domain predictions to generate clinical proof...
Researchers at the MRC Laboratory of Medical Sciences have engineered plants to glow when their immune systems are activated, using a bioluminescent pathway from mushrooms linked to the plant hormones salicylic and jasmonic acid. The genetically modified Nicotiana benthamiana and...
The FDA has cleared Mammotome’s Mammotome Prima MR Dual Vacuum‑Assisted Breast Biopsy System and its HydroMARK Plus MR biopsy site marker, marking the first in‑room MR‑guided biopsy solution. The system positions the vacuum‑assisted device beside the patient in the scanner, reduces...
Cosmos Health Inc. announced it will release revised operational, strategic and financial guidance following its FY2025 results, highlighting a projected $12 million-plus annual revenue stream from its NOOR Collagen line in the United States and gross margins near 75%. The update...
Nautilus Biotechnology has enrolled Baylor College of Medicine as the first participant in its Voyager early‑access program, granting the school access to a single‑molecule proteomics platform capable of mapping up to 10 billion intact proteins per run. The collaboration, funded by...
BIOTECanada has praised the federal government’s launch of the Pharmaceutical and Life Sciences Sector Task Force, signaling a strategic push to strengthen Canada’s biotech and pharma ecosystem. The task force is tasked with reviewing investment incentives, regulatory frameworks, and market...
Johns Hopkins received a five‑year, $15 million NIH grant to build the Drug Research Organoid Intelligence Development Platform (DROIDp). The platform will combine human brain organoids, advanced electrical sensors and AI analytics to evaluate learning, memory and neurotoxicity. It targets Alzheimer’s,...
On December 2025 the FDA officially qualified dual‑energy X‑ray absorptiometry (DXA) bone density scans as the first surrogate endpoint for fracture outcomes in osteoporosis trials involving post‑menopausal women. The qualification, achieved through a request from the Foundation for the National...
The FDA has added a new warning to the Gilenya (fingolimod) label after identifying 35 cases where patients experienced severe disability following drug discontinuation. The worsening, which can occur 2 to 24 weeks after stopping treatment, often exceeds typical MS...
Pacific Northwest National Laboratory has merged AI with high‑throughput robotics to speed microbial biotechnology development. Researchers adapted the open‑source BacterAI platform to model continuous growth‑boundary conditions, then paired it with a Tecan Fluent liquid‑handling system that can execute thousands of...
Katrine Bosley: There's no question “hopes and aspirations” got ahead of the pace of any new science on gene editing #STATBreakthrough Seng Cheng: “The promise of gene therapy is correct. I think it has made that promise. and that's demonstrated by...
Jane Grogan from $BIIB again, on the fundamental challenge of drug discovery: do you believe what early experiments tell you? "We need to understand when [models] can be predictive and when they help at answering our hypothesis... “If you...
$BIIB’s Jane Grogan on the impact of China on biotech innovation. “There's three times more PhDs that have been given last year in China than in the US. ... That's a lot of bright young things out there who are going...
$BMY chief scientist Robert Plenge: says there is “a joke” drug developers often repeat. “It's an overnight sensation a decade in the making. These things can actually be going on for a very long time, and then suddenly the field catches...
But one set of trials (TAD) were open label and other set of trials (psychedelic) included impt elements of experimental control, procedures like randomization and blinding. Does functional unblinding mid-session justify treating these trials as procedurally equivalent? No.
This week's Biotech Scorecard newsletter: Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era $REPL Pierre Fabre $ATRA $QURE $CAPR $RGNX https://t.co/sGa7G6YTDn
New @ScienceMagazine Discovery of a circuit that connects stress and skin inflammation https://t.co/Dkmmcs96JT https://t.co/chrXyKrG2N https://t.co/7nOPn9fCoU
Very positive development for $SRRK - Genentech ceases drug development to spinal muscular atrophy - puts SRRK clearly in the lead Cantor on it now https://t.co/IjCyBm2Kcv
This definitely looks like a cardiac safety signal at the higher doses. The GLP-1's all slightly increase pulse rate as a starting point.
The Financial Times covered recent initiatives at Cancer Research UK (CRUK) including a nice piece on the ongoing Aleta Biotherapeutics clinical trial in CD19-CAR-T treated B cell lymphoma patients. https://t.co/9sDZEItapu
